AB-SA01
AXP000222.1 · Phage therapy
- Platform
- phage cocktail (fixed composition, three phages)
- Originator
- AmpliPhi Biosciences
- Sponsor
- Armata Pharmaceuticals
Names
| Name | Type | Source |
|---|---|---|
| AB-SA01 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Herelleviridae
- Virus
- Staphylococcus phage K-related bacteriophage (three-phage cocktail)
- Replication
- replicating
- Route
- intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02757755 | Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults | Completed | Phase 1 | 2016-05 | 2016-08 | 12 | Healthy Volunteers |
| NCT03395769 | Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic | No longer available |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32066959 | Safety of bacteriophage therapy in severe Staphylococcus aureus infection. | Nature microbiology | 2020 | name in abstract: AB-SA01 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38347019 | Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers. | Scientific reports | 2024 | name in abstract: AB-SA01 |
| PMID 32443619 | Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms. | Viruses | 2020 | name in abstract: AB-SA01 |
| PMID 32646376 | Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. | BMC microbiology | 2020 | name in title: AB-SA01 |
| PMID 33077648 | Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model. | Antimicrobial agents and chemotherapy | 2020 | name in title: AB-SA01 |
| PMID 30669652 | Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections. | Viruses | 2019 | name in abstract: AB-SA01 |
| PMID 31219531 | Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus. | JAMA otolaryngology-- head & neck surgery | 2019 | name in abstract: AB-SA01 |
Notes
Fixed-composition product of three obligately lytic myoviruses related to Staphylococcus phage K (Lehman 2019, Viruses 11:88). Given intravenously to 13 patients with severe S. aureus infection in an open single-arm study (Petrovic Fabijan 2020, Nat Microbiol 5:465-472) and in Australian compassionate cases; US expanded-access record NCT03395769. AmpliPhi Biosciences was renamed Armata Pharmaceuticals in 2019. virus_family is given as Herelleviridae because phage K is a Kayvirus of that family; the source itself says only 'myoviruses related to phage K'.
How to cite
AB-SA01 (AXP000222.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000222.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.